Bell R L, Young P R, Albert D, Lanni C, Summers J B, Brooks D W, Rubin P, Carter G W
Immunoscience Research Area and Immunoscience Venture, Abbott Laboratories, Abbott Park, IL 60064.
Int J Immunopharmacol. 1992 Apr;14(3):505-10. doi: 10.1016/0192-0561(92)90182-k.
The enzyme 5-lipoxygenase is a key target in the effort to discover drugs which inhibit the pathophysiology associated with the formation of leukotrienes. The research efforts of these laboratories have focused on the discovery of direct enzyme inhibitors of 5-lipoxygenase. In particular, compounds with hydroxamate or N-hydroxyurea functionalities have proven to be potent inhibitors of leukotriene biosynthesis in vitro and more importantly in vivo. One of these compounds, zileuton (N-(1-benzo-[b]-thien-2-ylethyl)-N-hydroxyurea) has been shown recently to be an effective leukotriene inhibitor in man. The critical approaches and breakthroughs in the discovery and development of zileuton are described. In addition, some recent results with zileuton in animals and man are detailed.
5-脂氧合酶是研发抑制与白三烯形成相关病理生理过程药物的关键靶点。这些实验室的研究工作聚焦于发现5-脂氧合酶的直接酶抑制剂。特别是,具有异羟肟酸酯或N-羟基脲官能团的化合物已被证明在体外尤其是在体内是白三烯生物合成的有效抑制剂。这些化合物之一,齐留通(N-(1-苯并[b]噻吩-2-基乙基)-N-羟基脲)最近已被证明在人体中是一种有效的白三烯抑制剂。本文描述了齐留通发现与开发过程中的关键方法和突破。此外,还详细介绍了齐留通在动物和人体中的一些最新研究结果。